Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Thyroid Cancer, Papillary 2Polycystic Ovary Syndrome 2Pituitary Neoplasms 2Neoplasms 2Diabetes Mellitus, Type 2 2Adenocarcinoma, Follicular 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Cancers 1Sezary Syndrome 1Sarcoma 1Prostatic Neoplasms 1Pituitary ACTH Hypersecretion 1Pancreatic Neoplasms 1Obesity 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Follicular 1Liposarcoma 1Leukoplakia, Oral 1Head and Neck Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Alzheimer Disease 1Adenocarcinoma Of Esophagus 1

Interventions

relacorilant 3Mifepristone 3Corlux 3Cabergoline 3pasireotide 2fimepinostat 1corticorelin ovine 1Tissue Banks 1Rosiglitazone 1Perceived Stress Scale 1Magnetic Resonance Spectroscopy 1Deamino Arginine Vasopressin 1Biomarkers 14-amino-4'-hydroxylaminodiphenylsulfone 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pituitary ACTH Hypersecretion × Rosiglitazone × Clear all
NCT00612066 2020-08-06

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
2 enrolled 5 charts
Endocrine

Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡